USD
+$0.00
(+0.00%
)At Close (As of Oct 16, 2025)
$1.48B
Market Cap
-
P/E Ratio
-0.7
EPS
$18.21
52 Week High
$6.78
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $414M |
Total Revenue | $611M |
Cost Of Revenue | $196M |
Costof Goods And Services Sold | $196M |
Operating Income | -$195M |
Selling General And Administrative | $339M |
Research And Development | $265M |
Operating Expenses | $609M |
Investment Income Net | - |
Net Interest Income | $18M |
Interest Income | $18M |
Interest Expense | $4K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $44M |
Income Before Tax | -$178M |
Income Tax Expense | $4.9M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$183M |
Comprehensive Income Net Of Tax | - |
Ebit | -$178M |
Ebitda | -$134M |
Net Income | -$183M |
Field | Value (USD) |
---|---|
Total Assets | $919M |
Total Current Assets | $584M |
Cash And Cash Equivalents At Carrying Value | $344M |
Cash And Short Term Investments | $344M |
Inventory | $83M |
Current Net Receivables | $88M |
Total Non Current Assets | $334M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $16M |
Intangible Assets Excluding Goodwill | $16M |
Goodwill | $4.5M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $49M |
Other Current Assets | $20M |
Other Non Current Assets | - |
Total Liabilities | $209M |
Total Current Liabilities | $118M |
Current Accounts Payable | $13M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $19M |
Total Non Current Liabilities | $91M |
Capital Lease Obligations | $83M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $83M |
Other Current Liabilities | $61M |
Other Non Current Liabilities | $5M |
Total Shareholder Equity | $710M |
Treasury Stock | - |
Retained Earnings | -$1.5B |
Common Stock | $2K |
Common Stock Shares Outstanding | $120M |
Field | Value (USD) |
---|---|
Operating Cashflow | $6.7M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $44M |
Capital Expenditures | $12M |
Change In Receivables | - |
Change In Inventory | -$9.8M |
Profit Loss | - |
Cashflow From Investment | -$33M |
Cashflow From Financing | $11M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$183M |
Field | Value (USD) |
---|---|
Gross Profit | $414M |
Total Revenue | $611M |
Cost Of Revenue | $196M |
Costof Goods And Services Sold | $196M |
Operating Income | -$195M |
Selling General And Administrative | $339M |
Research And Development | $265M |
Operating Expenses | $609M |
Investment Income Net | - |
Net Interest Income | $18M |
Interest Income | $18M |
Interest Expense | $4K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $44M |
Income Before Tax | -$178M |
Income Tax Expense | $4.9M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$183M |
Comprehensive Income Net Of Tax | - |
Ebit | -$178M |
Ebitda | -$134M |
Net Income | -$183M |
Sector: HEALTHCARE
Industry: HEALTH INFORMATION SERVICES
10X Genomics, Inc. is a premier life science technology company focused on delivering innovative genomic analysis solutions that empower researchers to dissect complex biological systems. With a comprehensive suite of advanced instruments, consumables, and analytical software, the company enhances the resolution and accuracy of genetic research. Operating from its headquarters in Pleasanton, California, 10X Genomics serves a diverse global market, catering to the dynamic needs of life sciences across North America, Europe, and Asia. The company’s steadfast commitment to advancement in genomic technologies positions it as a critical player in the ever-evolving landscape of biological research and discovery.